119 – Emerging Trends in Regulatory Science (S8E14)

All right, welcome to the Deep Dive. Today, we're
gonna be digging into some really fascinating
stuff. It's all about how things are changing
in the world of regulatory science. You know,
the whole process of getting those new medicines
out to people. Absolutely, and we've got a whole
bunch of recent studies and papers and things
really trying to understand how these new technologies
are transforming everything. We're talking adaptive
pathways, AI, real -time monitoring. the whole
shebang. So basically how are these things making
drug approvals faster, making sure they're safe
and streamlining all that compliance stuff. Exactly.
We want to give you the key takeaways without
getting bogged down in all the super technical
details. Perfect. So let's kick things off with
this idea of adaptive pathways. Now, traditionally,
drug development has been this very structured
kind of step -by -step process, right? Yeah.
You've got your drug discovery, preclinical testing,
then those clinical trials. And finally, if everything
looks good, you get approval. It's a long road.
Yeah. The drug development. From discovery to
market source lays it all out. But these adaptive
pathways, they seem to be shaking things up.
They are. It's a much more flexible approach,
much more iterative. So instead of waiting for
tons of data before a drug can even be considered,
adaptive pathways might allow patients to access
promising treatments earlier, especially for
serious conditions. Right, and the key here is
that the data collection doesn't stop once the
drug's out there. You're constantly gathering
more information on how it's working, what the
risks are, all of that. That's a really interesting
point. So for people with life -threatening illnesses,
this could mean getting access to potentially
life -saving treatments much sooner. But how
do regulators make sure it's safe? Well, it's
not about lowering the bar for safety. It's more
about acknowledging that with certain diseases,
our understanding evolves as we see how a drug
performs in the real world outside of those controlled
clinical trials. Right, so real -world evidence
becomes this crucial piece of the puzzle. Exactly.
Think of it like, you know, in the past you'd
have to wait for the entire painting to be finished
before you could see it. Adaptive pathways are
like unveiling parts of the painting as it's
being created, letting people see the progress
while still making sure the whole thing comes
together beautifully. I love that analogy. It
really captures the balance between urgency and
continued evaluation. Okay, let's shift gears
now and talk about AI. Everyone's talking about
AI these days. What's its role in regulatory
science? It's huge. Like in our season two deep
dives, AI is like this super powered research
assistant. It can analyze these massive data
sets way beyond what humans can do and find these
subtle patterns, make predictions. It's really
amazing. So instead of scientists spending years
pouring over data, AI can sort of do the heavy
lifting and uncover insights that might have
been missed. Exactly. And it's being used in
all sorts of ways, from analyzing medical images
to predicting how individual patients might respond
to treatments. So for example, in those Philips
patents we saw, AI can analyze medical images
like MRIs and CT scans and help doctors make
better decisions. Right. And they've even got
patents on how to pre -process that imaging data
to make the AI even more accurate. It's like
giving the AI better tools to work with. So imagine
AI going through millions of records and spotting
a rare drug interaction that might have slipped
past human researchers. That could prevent so
many problems down the line. Absolutely. And
those Phillips patents also talk about these
really cool personalized models. They can predict
how a treatment might affect a patient's quality
of life, not just whether it works or not. Wow,
so AI could help doctors understand how a treatment
will affect a patient's day -to -day life, not
just their disease. That's incredible. And it's
not just imaging and prediction. AI is being
used to develop rapid diagnostic tools. Like,
there's this e -tool from Stryker that uses AI
to diagnose strokes super quickly. That's so
important in stroke cases where every minute
counts. So AI isn't just making things faster.
It's actually improving outcomes for patients.
It is, and it's even changing how we discover
and develop drugs in the first place. AI can
analyze protein structures and predict which
ones are most likely to be drugable, meaning
they'll interact with a drug. So it's helping
scientists design better drugs from the very
beginning. Exactly. It's like finding the right
key for a specific lock. But we have to remember
that AI is only as good as the data it learns
from. If the data is biased, the AI will be biased
too. So we need to be really careful with how
we develop and use it. That's a great point.
Okay, let's move on to our last trend, real -time
monitoring. What exactly does that mean in regulatory
science? It basically means we're constantly
collecting and analyzing data to make sure drugs
are safe and that everything's compliant. So
it's not just about checking in at certain points.
It's about having a continuous stream of information.
Exactly. And we're talking about using real -world
data from electronic health records, wearable
devices, all sorts of things. That gives us a
much better picture of how a drug is performing
in a real -world setting. So it's like having
this ongoing feedback loop, constantly assessing
the safety and effectiveness of a drug. Right.
And it applies to manufacturing, too. This is
where process analytical technology, or PT, comes
in. It's all about designing and controlling
manufacturing processes using real -time measurements.
It's like having sensors in a factory that constantly
check the quality of the product as it's being
made. Exactly. It's about continuous quality
assurance. If something goes wrong, you catch
it immediately and fix it. Makes sense. So how
do these three trends we've talked about, adaptive
pathways, AI, and real -time monitoring, how
do they all work together to make drug approvals
faster? They each have their own role to play.
Adaptive pathways allow for more flexible approvals,
AI speeds up the early stages of drug development,
and real -time monitoring streamlines the whole
compliance process. So it's not about rushing
things, but about using technology to get safe
and effective medicines to patients as quickly
as possible. Exactly. And they also make safety
assessments much more robust. Adaptive pathways
allow for ongoing monitoring in the real world,
AI can spot potential safety signals that might
have been missed, and real -time monitoring ensures
consistent quality in manufacturing. It's like
having this multi -layered safety net. Exactly.
And even after a drug's approved, we can keep
monitoring for any long -term side effects that
might emerge. Now, you mentioned quality by design
or QBD. Could you briefly explain what that entails?
Sure. QBD is a really important concept. It's
about building quality into the entire process
from the very beginning. So instead of just testing
the final product, you're constantly monitoring
and controlling everything to make sure you're
getting a high quality product every time. Right.
It's a more proactive approach. Now, I know our
listeners always like to hear real world examples.
They do. It helps to make things more concrete.
Right. While our sources don't have a specific
case study that that combines all three of these
trends in a single drug approval, we can still
highlight some cool examples of AI in action.
Great. Let's hear them. So we've got Philips
developing AI -powered tools to help doctors
interpret medical images. That's already happening,
and it's making a big difference. And then there's
Stryker's AI tool for rapid stroke diagnosis.
That's saving lives by getting people the treatment
they need faster. So, even though we don't have
a single case study that perfectly encapsulates
everything, these examples show how AI is already
transforming healthcare, and that's definitely
going to have an impact on regulatory science.
And those discussions around PET and manufacturing,
that shows how important real -time monitoring
is becoming. It's not just about drugs. It's
about ensuring quality across the board. Absolutely.
And it all points to a future where regulatory
oversight is more dynamic, more data -driven,
and more patient -centered. It sounds like a
very exciting future for regulatory science.
So to wrap things up, let's recap our key takeaways.
We learned about adaptive pathways and how they
offer a more flexible route to drug approval.
We explored the power of AI in analyzing data
and making predictions to accelerate drug development
and enhance safety assessments. And we discussed
the crucial role of real -time monitoring in
ensuring quality and streamlining compliance.
All of these trends are coming together to shape
a future where new medicines can reach patients
more quickly and safely. Absolutely. And on that
note, I'd like to leave our listeners with a
final thought. As these technologies continue
to evolve, how do you think the role of regulatory
agencies will change? How will they balance the
need for innovation with the need to protect
patient safety? It's a complex question with
no easy answers, but it's definitely something
worth pondering. Thanks for joining us on the
Deep Dive. Thanks for having me. It's been a
pleasure.